• Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monconduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A.M., Sotto, J.J., Wetterwald, M., Dumontet, C., Fuzibet, J.G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J.L., Facon, T. & Mathiot, C. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood, 109, 34893495.
  • Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q.L., Chen, C.I., Reece, D., Chun, K. & Keith Stewart, A. (2004) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology, 125, 6468.
  • Chang, H., Qi, C., Yi, Q.L., Reece, D. & Stewart, A.K. (2005) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood, 105, 358360.
  • Chng, W.J., Glebov, O., Bergsagel, P.L. & Kuehl, W.M. (2007) Genetic events in the pathogenesis of multiple myeloma. Best Practice & Research. Clinical Haematology, 20, 571596.
  • Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., Van Ness, B., Van Wier, S.A., Henderson, K.J., Bailey, R.J. & Greipp, P.R. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 45694575.
  • Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Greipp, P.R., Litzow, M.R., Henderson, K.J., Van Wier, S.A., Ahmann, G.J. & Fonseca, R. (2005) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood, 106, 28372840.
  • Gutierrez, N.C., Castellanos, M.V., Martin, M.L., Mateos, M.V., Hernandez, J.M., Fernandez, M., Carrera, D., Rosinol, L., Ribera, J.M., Ojanguren, J.M., Palomera, L., Gardella, S., Escoda, L., Hernandez-Boluda, J.C., Bello, J.L., De La Rubia, J., Lahuerta, J.J. & San Miguel, J.F. (2007) Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia, 21, 143150.
  • Hanamura, I., Iida, S., Akano, Y., Hayami, Y., Kato, M., Miura, K., Harada, S., Banno, S., Wakita, A., Kiyoi, H., Naoe, T., Shimizu, S., Sonta, S.I., Nitta, M., Taniwaki, M. & Ueda, R. (2001) Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Japanese Journal of Cancer Research, 92, 638644.
  • Stralen, E., Leguit, R.J., Begthel, H., Michaux, L., Buijs, A., Lemmens, H., Scheiff, J.M., Doyen, C., Pierre, P., Forget, F., Clevers, H.C. & Bast, B. (2009) MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. Leukemia, 23, 801803.
  • Van Stralen, E., Van De Wetering, M., Agnelli, L., Neri, A., Clevers, H.C. & Bast, B.J. (2009) Identification of primary MAFB target genes in multiple myeloma. Experimental Hematology, 37, 7886.